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Introduction {#sec001}
============

The Serum Bactericidal Activity (SBA) assay assesses the complement-dependent bactericidal activity of antibodies in sera against bacterial isolates. This assay is the method of choice to evaluate the complement-mediated functional activity of both infection- and vaccine-induced antibodies \[[@pone.0172163.ref001]--[@pone.0172163.ref003]\]. For *Neisseria meningitidis*, SBA is the accepted correlate of protection on which meningococcal vaccines are registered \[[@pone.0172163.ref004], [@pone.0172163.ref005]\]. Bactericidal assays have been developed also for other pathogenic microorganisms \[[@pone.0172163.ref006]--[@pone.0172163.ref008]\] like *Neisseria gonorrhoeae*, *Haemophilus influenza* and *Vibrio cholerae* for which it is considered the gold standard of protection \[[@pone.0172163.ref009]\]. Additionally, SBA assays have been further used to assess naturally acquired-antibody responses, determining, for example, the relation between age-specific prevalence of specific diseases and presence of bactericidal antibodies \[[@pone.0172163.ref010]\]. In order to perform a typical SBA assay, serial dilutions of sera are incubated with target bacterial strains and an exogenous source of active complement \[[@pone.0172163.ref004]\]. Pathogen-specific antibody binds to the bacterial surface via specific protein or carbohydrate moieties. The C1q subunit of C1 complement protein binds to the Fc portion of the surface-bound Ig and such binding activates the classical pathway of complement, which ultimately results in death of the target organism. The serum killing activity is then evaluated by plating the SBA reaction mix and counting the surviving bacterial colony forming units (CFU) at each serum dilution. Bactericidal antibody titers are usually calculated as the reciprocal dilution of test serum that kills ≥ 50% of the bacteria in the assay \[[@pone.0172163.ref011]\].

The conventional SBA assay is labor-intensive, time-consuming and not amenable to the evaluation of large numbers of serum samples. Although automated colony counting may be used, the process is mostly performed manually, and inter-operator variability is an established source of error when an assay is being qualified for clinical trials. SBA methods have proven difficult to standardize among laboratories \[[@pone.0172163.ref005]\], and with the method's cumbersomeness, there is urgent need to develop a sensitive and high-throughput assay for a rapid and robust assessment of presumed vaccine effectiveness. For this reason, recently, fluorescence- or colorimetric-SBA assays have been proposed to replace CFU plate counting \[[@pone.0172163.ref012]--[@pone.0172163.ref014]\].

In this study, we describe a luminescence-based SBA (L-SBA) assay where bacteria surviving the complement-mediated antibody dependent killing are detected by measuring their metabolic ATP via a novel application of the commercially available BacTiter-Glo Reagent (Promega). The manufacturer describes BacTiter-Glo as a homogenous method for determining the number of viable bacterial cells in culture based on quantitation of the ATP present. This reagent contains a lysis buffer together with a thermostable luciferase and its substrate luciferin that in the presence of ATP is oxidized with the emission of light. L-SBA adheres to the same assay principle as the conventional SBA, but differs in that the bactericidal reaction mix is not plated on agar plates, rather is mixed with this reagent. Bacterial cell lysis is induced and bacterial ATP becomes available to trigger the luciferase-mediated reaction, resulting in a measurable luminescence signal. The signal obtained is proportional to the ATP present in the SBA reaction mix, and is directly proportional to the number of bacteria which were not killed by SBA. Therefore, the bactericidal titer can be calculated directly from the microplate, at the end of the bactericidal reaction, using a luminometer.

We showed that L-SBA can be used with a range of different microorganisms: *Citrobacter freundii*, *Salmonella enterica* serovars Typhimurium and Enteritidis, *Shigella flexneri* serotypes 2a and 3a, *Shigella sonnei*, and *Neisseria meningitidis* serogroups A and W, allowing determination of bactericidal titers of different post-immunization mouse sera. We demonstrated consistent results and a strong correlation between serum titers, as determined by traditional CFU counting method and by L-SBA. We propose L-SBA as a universal alternative readout method for bactericidal reactions against different bacterial species and strains.

Materials and methods {#sec002}
=====================

Bacterial strains and reagents {#sec003}
------------------------------

All bacterial strains used in this study (described in [Table 1](#pone.0172163.t001){ref-type="table"}) were stored frozen at -80°C in 20% glycerol stocks. *Citrobacter*, *Salmonella* and *Shigella* strains were grown at 37°C in Luria Bertani (LB) medium. In the case of *Shigella* strains, an overnight culture was started from frozen stock cultures. The bacterial suspension was then diluted 1:100 in fresh LB and incubated at 37°C with 180 rpm agitation in an orbital shaker, until they reached an optical density at 600 nm (OD~600~) of 0.2. *Citrobacter* and *Salmonella* strains from frozen glycerol stocks were grown in LB to log phase (0.2 OD~600~) and then diluted to approximately 1 x 10^6^ CFU/mL in phosphate-buffered saline (PBS). Meningococcal strains were grown on GC agar plates (Difco Laboratories, Detroit, Mich.), and the plates were incubated overnight at 37°C in 5% CO~2~. A portion of the plated overnight culture was used to inoculate fresh Mueller Hinton Broth (MHB) (Difco Laboratories, Detroit, Mich.) supplemented with 0.25% (w/v) glucose in a 16 mL-tube. Cultures were incubated at 37°C in 5% CO~2~, shaking, until they reached approximately 0.65 OD~600~. The bacterial suspension was then diluted 1:6 in a new 16 mL-tube with pre-warmed MHB medium supplemented with 0.25% glucose and 0.02 mM Cytidine-5'-monophospho-N-acetylneuraminic acid (CMP-NANA) (Sigma). The cultures were incubated at 37°C in 5% CO~2~ until they reached approximately 0.65 OD~600~. Meningococcal bacteria were then washed once in Dulbecco's PBS (DPBS) (Sigma) with 1% (w/v) bovine serum albumin (BSA) (Sigma), and then diluted to approximately 1 x 10^6^ CFU/mL in DPBS-1% BSA.

10.1371/journal.pone.0172163.t001

###### Bacterial strains used in this study.

![](pone.0172163.t001){#pone.0172163.t001g}

  Species and serovar                         Strain       Isolation location or characteristics                      Reference(s) or source
  ------------------------------------------- ------------ ---------------------------------------------------------- ----------------------------------------------------
  *Citrobacter freundii*                      3056         Clinical isolate from Novartis Master Culture Collection   \[[@pone.0172163.ref015]\]
  *Salmonella enterica* serovar Typhimurium   D23580       Clinical isolate from blood culture, Malawi                \[[@pone.0172163.ref010], [@pone.0172163.ref016]\]
  *Salmonella enterica* serovar Enteritidis   Ke016        Gastrointestinal isolate, Kenya                            \[[@pone.0172163.ref017]\]
  *Shigella flexneri* serotype 2a             142          Clinical isolate                                           Public Health England (PHE) culture collection
  *Shigella flexneri* serotype 3a             144          Clinical isolate                                           Public Health England (PHE) culture collection
  *Shigella sonnei*                           71           *S*. *sonnei* 53G Δ*virG*::*cat*                           \[[@pone.0172163.ref018]\]
  *Neisseria meningitidis* serogroup A        Niga 16/09   Clinical isolate, Nigeria                                  Norwegian Institute of Public Health
  *Neisseria meningitidis* serogroup W        Mali 4/11    Clinical isolate, Mali                                     Norwegian Institute of Public Health

Serum samples {#sec004}
-------------

The serum samples used were obtained from mice immunized with conjugates or with Generalized Modules for Membrane Antigens (GMMA)-based vaccines \[[@pone.0172163.ref018], [@pone.0172163.ref019]\]. For tests involving *Citrobacter freundii* 3056 a standard reference pooled serum raised to Vi-CRM~197~ vaccine conjugate \[[@pone.0172163.ref015], [@pone.0172163.ref020]\] was used. Bactericidal activity against *S*. Typhimurium and *S*. Enteritidis was assessed using a standard reference pooled serum raised to *S*. Typhimurium (STm) and *S*. Enteritidis (SEn) GMMA vaccines, respectively. Additionally, individual mouse sera raised to STm and SEn GMMA or O-antigen-CRM~197~ conjugates, with different bactericidal potential, were also included in these tests. Bactericidal activity against *Shigella flexneri* and *Shigella sonnei* \[[@pone.0172163.ref018]\] was assessed using three reference standard pooled sera raised against GMMA purified from the homologous strains. Bactericidal activity against *Neisseria meningitidis* was assessed using mouse pooled sera raised to different doses of meningococcal GMMA. Additionally, anti-capsular monoclonal antibodies (mAb), specific for serogroups A and W (generously provided by Dan Granoff and Jo Anne Welsch, CHORI, US), were also used. All sera tested in SBA were previously heat-inactivated (HI) at 56°C for 30 minutes to remove endogenous complement activity.

Conventional SBA {#sec005}
----------------

Log-phase cultures were prepared as described above and diluted to approximately 1 x 10^6^ CFU/mL in the assay diluent (PBS or DPBS-1% BSA for *N*. *menigitidis*). The reaction mixtures were prepared in a 96-well round bottom microtiter plate in a final volume of 100 μL, containing 10 μL of the target bacterial cells, 10 μL of HI serum or mAb (2-fold or 1.5-fold serially diluted) and baby rabbit serum (BRS) as external source of complement (Pelfreeze from Invitrogen and Cederlane from Euroclone). For each tested strain we initially determined the optimal lot and percentage of BRS to be used, which lacked intrinsic bactericidal activity. Specifically, we used 5% BRS for *C*. *freundii*, 15% BRS for *S*. *flexneri*, 20% BRS for *S*. *sonnei* and *N*. *menigitidis* strains, and finally 50% BRS for *S*. Typhimurium and Enteritidis strains, as previously published \[[@pone.0172163.ref021]\]. Negative controls were also included, represented by active BRS without any antibody source and HI BRS. The plates containing the reaction mixtures were incubated for 3 hours at 37°C, in air with 5% CO~2~ for *N*. *meningitidis* or without added CO~2~ for other bacteria. At time zero (T0) and at the end of incubation, serial dilutions of the reactions were spread onto LB or GC-agar plates and grown overnight. Colonies were counted after 16 h incubation and SBA titers were calculated as the reciprocal serum dilution necessary to obtain 50% reduction in relation to the maximum growth of bacteria obtained in the test \[[@pone.0172163.ref001], [@pone.0172163.ref022]\].

Luminescent-SBA (L-SBA) {#sec006}
-----------------------

L-SBA adheres to the same assay principles as the conventional SBA, but diverges in the readout method. The reaction mixtures were prepared in a 96-well microtiter plate as described above. At the end of the bactericidal reaction, the SBA plate was centrifuged at room temperature (RT) for 10 minutes at 3220×*g*. The supernatant was discarded from all the wells to remove ATP derived from dead bacteria and SBA reagents, and the remaining live bacterial pellets were resuspended in PBS or DPBS-1% BSA in the case of *N*. *meningitidis*. From each well, 50 μL of bacterial suspension was transferred to a white flat-bottom 96-well microtiter plate (Greiner) and 50 μL of the commercially available BacTiter-Glo Reagent (Promega) was added to each well. The reaction was incubated for 5 minutes at RT on an orbital shaker, and then the luminescence signal measured by a luminometer (Victor 2, Wallac from PerkinElmer). In the same way, luminescence was acquired prior to start incubation, at time zero (T0), in a well containing bacteria and buffer, in order to estimate the signal released from the initial concentration of bacteria. The luminometer expresses luminescence as counts per second (CPS). For each well, the average CPS of three consecutive measurements per well was used, using the software Wallac 1420 Workstation. A blank well containing only dilution buffer was included in each plate and the background CPS was subtracted from the samples CPS values. For each tested serum, a bacterial growth inhibition curve was obtained plotting luminescence signal at each serum dilution. As for the conventional SBA assay, bactericidal serum titers were calculated as the reciprocal serum dilution necessary to obtain 50% bacterial growth inhibition.

Curve fitting and statistical analysis {#sec007}
--------------------------------------

Raw values from each bactericidal reaction in the presence of test serum (CPS~test180~) were normalized to the maximum bacterial growth obtained after 3 h (180 min, T180) incubation (CPS~max180~), by calculating CPS~test180~/CPS~max180~ or CFU~test180~/CFU~max180~. Normalized data were then analyzed by a four-parameter logistic (4-PL) curve fitting model, using GraphPad Prism 6 software (GraphPad Software, La Jolla, CA). The reciprocal serum dilution that resulted in a 50% reduction of luminescence or CFU counts normalized per the maximum signal (in terms of luminescence or CFU counts detected at the highest serum dilution, equal to the signal given by the complement controls) was reported as the titer of the serum sample, as well as for mAb when used in the experiments. The normalization was convenient to plot multiple data sets on the same scale and had no impact in determining the bactericidal titer. However, we noticed that the variation in the maximum growth of the different bacteria in the assay condition influences the baseline of the bactericidal curves, which may vary between 0.1 (less bacterial growth) and 0.01 (higher bacterial growth).

To evaluate reproducibility of SBA assays, 3 independent experiments were performed and mean titers value ± standard deviation (SD) was determined for each serum from the three experiments. Inter-assay variation was also calculated and reported as coefficient of variation (CV) which is the standard deviation divided by the mean. Serum titers from triplicates were assessed and reported with the 95% Confidence Interval (CI) limit values.

To examine the correlation between serum titers determined by traditional CFU counting method and by L-SBA, the results were plotted against each other, and Pearson correlation coefficient (*r*) and *P* value were obtained using GraphPad Prism 6 software.

Ethical statement {#sec008}
-----------------

All animal sera used in this study derived from mouse immunization experiments performed at the Novartis Vaccines Animal Facility in Siena, Italy, (now acquired by the GSK group) in compliance with the relevant guidelines of Italy (Italian Legislative Decree n. 116/1992) and the institutional policies of Novartis Vaccines (now acquired by the GSK group). The animal protocol was approved by the Animal Welfare Body of Novartis Vaccines, Siena, Italy, (now acquired by the GSK group) and by the Italian Ministry of Health (Approval number AEC201018).

Results {#sec009}
=======

Determination and optimization of assay parameter values {#sec010}
--------------------------------------------------------

### Bacterial cell concentration, sensitivity and linearity range {#sec011}

The first step to develop a useful readout method, to allow bacteria quantification directly from the wells where the SBA reaction has taken place, consisted of determining the optimal bacterial cell concentration to maximize reagent's sensitivity. For these preliminary set up tests, we decided to use *Citrobacter freundii*, being an easy to handle BSL-1 microorganism. With the aim of assessing the viability and growth of bacteria, different bacterial concentrations, ranging from 1 x 10^3^ to 1 x 10^5^ CFU/mL were tested in a SBA-like reaction mixture, containing 5% BRS as complement source (and growth factor) in the assay diluent only, without serum. Luminescence was measured following the addition of BacTiter-Glo Reagent at T0 and at T180. Bacterial CFU were also counted on agar-plates the following day. As shown in [Fig 1A](#pone.0172163.g001){ref-type="fig"}, the highest span of luminescence between T0 and T180 was obtained using 1 x 10^5^ CFU/mL bacteria in the well (4252 CPS difference compared to 91 CPS difference when 1 x 10^3^ CFU/mL were used at T0, see [S1 Table](#pone.0172163.s001){ref-type="supplementary-material"}). When bacterial cells were diluted from 1.5 x 10^5^ CFU/mL down to 1 x 10^3^ CFU/mL, a very good linear relationship between luminescence and cell concentrations by CFU counts was found (*r* \> 0.99, *p* \< 0.0001) ([Fig 1B](#pone.0172163.g001){ref-type="fig"}), hence 1 x 10^5^ CFU/mL was selected as suitable bacterial concentration for L-SBA setup. Higher bacterial concentrations were not tested because we have already shown that higher starting CFU/mL translates into a higher resistance to complement-mediated killing, thus requiring very high amount of BRS (75%) \[[@pone.0172163.ref023]\].

![Optimization of bacterial cell concentration for L-SBA.\
(A) Different bacterial concentrations were tested with 5% BRS and measured by luminescence at T0 (triangle symbol) and at T180 (square symbol). (B) Bacterial cells at 1.5 x 10^5^ CFU/mL were diluted down until 1.0 x 10^3^ CFU/mL and measured by luminescence. The area within the dashed lines define the confidence interval of the best-fit line of the linear regression (y = 0.009465x + 10.28). CPS, counts per second.](pone.0172163.g001){#pone.0172163.g001}

### L-SBA initial set up using *C*. *freundii*: Circumventing serum interference with luminescence readout {#sec012}

In the initial setup tests, we observed a high interference in the luminescence acquisition caused by the reagents used in the SBA reaction mixture, especially by the BRS when used at high concentrations (50%) ([S1 Fig](#pone.0172163.s002){ref-type="supplementary-material"}). More specifically, we found that measuring by luminescence the killing effect of 50% BRS for *Citrobacter freundii* (BRS at this concentration is toxic for the microorganism, inducing 99% killing), luminescence was overestimated and unable to reliably quantify the surviving bacteria, while, adding one single washing step, it decreased by almost three times (252 CPS instead of 796 CPS), thus correlating with the expected CFU ([S1 Fig](#pone.0172163.s002){ref-type="supplementary-material"}). Several tests were performed with *C*. *freundii* in the presence of 5% BRS and serial dilutions of HI standard reference serum ([Fig 2](#pone.0172163.g002){ref-type="fig"}) to determine the optimum washing procedure for the elimination of the interference and the reproducibility of measuring the collected live bacteria. Each condition was repeated in three independent experiments. We found that a single spin and resuspension in PBS was sufficient to remove background interference. By contrast, adding more washes with PBS led to loss of bacterial cells and higher standard deviation bars, hence an increased variability in the bactericidal curves ([Fig 2](#pone.0172163.g002){ref-type="fig"}). In the bactericidal curves of *C*. *freundii* ([Fig 2](#pone.0172163.g002){ref-type="fig"}) a prozone effect was observed at higher serum concentrations (50- and 100-fold dilutions), where the signal was higher compared to what found at lower concentration (200-fold dilution). Such phenomenon may be due to either antibody excess or presence of nonspecific inhibitors in serum, which may inhibit the killing exerted at high serum concentrations \[[@pone.0172163.ref024]\].

![L-SBA optimization to circumvent serum interference with luminescence readout.\
Bactericidal reaction was tested using *C*. *freundii* in the presence of 5% BRS and serial dilutions of HI standard serum. At the end of the SBA reaction, we performed: a. one spin and resuspension of bacterial pellets in PBS; b. one wash; c. two washes in PBS, before measuring luminescence. Average luminescence signals and standard deviations are shown from three independent experiments, for each condition (for some points the error bars are not visible because shorter than the symbols).](pone.0172163.g002){#pone.0172163.g002}

Comparison of assays {#sec013}
--------------------

The relative performance of L-SBA including a single spin and resuspension was assessed for reproducibility, robustness, and comparison with the results of the conventional SBA. SBA assays were tested for clinically relevant pathogenic strains, such as *S*. Typhimurium, *S*. Enteritidis, *Shigella flexneri* serotypes 2a and 3a, *Shigella sonnei* and *Neisseria meningitidis* serogroups A and W.

### L-SBA evaluation using *Shigella flexneri* 2a and 3a and standard reference sera {#sec014}

Reference standard sera raised to the homologous strains (strain 142 for *S*. *flexneri* 2a and strain 144 for *S*. *flexneri* 3a) were tested, with each bactericidal reaction simultaneously assayed by both the conventional SBA (plating and CFU counts), and L-SBA. Similar bactericidal curves were obtained when SBAs against *S*. *flexneri* 2a or 3a were analyzed in terms of CFU counts and of luminescence signal ([Fig 3](#pone.0172163.g003){ref-type="fig"}), and good fits to a 4 parameter curve were obtained, especially using luminescence signal (*R*^*2*^ \> 0.98) ([Table 2](#pone.0172163.t002){ref-type="table"}). Similar serum titers were obtained by both methods, as shown in [Table 2](#pone.0172163.t002){ref-type="table"}. L-SBA was able to generate reproducible results, with very low variability especially with *S*. *flexneri* 2a (3% coefficient of variation CV compared to 17% CV for CFU titer) ([Table 2](#pone.0172163.t002){ref-type="table"}).

![Comparison of L-SBA and conventional SBA assay with standard reference sera against *Shigella flexneri* serogroups 2a and 3a.\
HI standard reference serum against *S*. *flexneri* 2a (A and B) and *S*. *flexneri* 3a (C and D) was tested by L-SBA (A and C, respectively) and by the conventional assay (B and D, respectively) in three independent experiments. Black lines represent the curve fitting by nonlinear regression for each replicate.](pone.0172163.g003){#pone.0172163.g003}

10.1371/journal.pone.0172163.t002

###### SBA titers against *S*. *flexneri* 2a and 3a as determined by L-SBA and by CFU counts-based method.

![](pone.0172163.t002){#pone.0172163.t002g}

                       test 1       test 2       test 3       Average      SD          CV %
  -------------------- ------------ ------------ ------------ ------------ ----------- --------
  ***S*. *flex 2a***                                                                    
  **L-SBA titer**      88662        94734        91261        **91552**    **3046**    **3**
  *R*^*2*^             *0*.*9819*   *0*.*9820*   *0*.*9957*                            
  **CFU titer**        82978        60520        83720        **75739**    **13186**   **17**
  *R*^*2*^             *0*.*9423*   *0*.*9703*   *0*.*9230*                            
  ***S*. *flex 3a***                                          ** **        ** **       ** **
  **L-SBA titer**      403554       345048       464769       **404457**   **59866**   **15**
  *R*^*2*^             *0*.*9954*   *0*.*9906*   *0*.*9974*                            
  **CFU titer**        382494       301295       320411       **334733**   **42452**   **13**
  *R*^*2*^             *0*.*9965*   *0*.*9923*   *0*.*9980*                            

### Bactericidal titers from L-SBA correlate with titers obtained in conventional SBA, using anti-STm and anti-SEn individual sera {#sec015}

To determine the relationship between the serum titers obtained in L-SBA and the titers from a conventional assay, a panel of eight individual mouse sera (4 raised against STm and other 4 raised against SEn) covering a broad range of titers was simultaneously assayed with the two methods ([Fig 4](#pone.0172163.g004){ref-type="fig"}). Plotting in the same graph the CFU counts based titers (*x* axis) and the L-SBA titers (*y* axis), we obtained good agreement between the two assays, as demonstrated by the Pearson correlation coefficient: *r =* 0.999, *p* \< 0.001 for STm SBA; *r* = 0.968, *p* \< 0.05 for SEn SBA ([Fig 4](#pone.0172163.g004){ref-type="fig"} and [Table 3](#pone.0172163.t003){ref-type="table"}), indicating a linear correlation.

![**Correlation of serum titers from individual mouse sera against *S*. Typhimurium (A) and *S*. Enteritidis (B) as determined by L-SBA and by the conventional SBA assay.** Individual mouse sera were simultaneously assayed by L-SBA (y-axis) and by the conventional CFU-based assay (x-axis) against *S*. Typhimurium (A) and against *S*. Enteritidis (B). Plots compare titers from each assay and demonstrate a linear correlation with a slope of 1. Black lines represent the fitting by linear regression. SBA titers were obtained by single experiments.](pone.0172163.g004){#pone.0172163.g004}

10.1371/journal.pone.0172163.t003

###### Linear regression values for data shown in [Fig 4](#pone.0172163.g004){ref-type="fig"}.

![](pone.0172163.t003){#pone.0172163.t003g}

  Serovar           *y*[^*1*^](#t003fn001){ref-type="table-fn"}    
  --------- ------- --------------------------------------------- -------
  STm       1.006   -0.098                                        0.986
  SEn       0.927   -0.034                                        0.938

^1^ y = ax + b, where a is the slope and b is the y intercept

### L-SBA can be applied to multiple bacterial species {#sec016}

To demonstrate that L-SBA can generate reproducible data, applicable to different strains and bacteria, we enlarged the panel of bacterial species tested by L-SBA. In addition to SBA against *C*. *freundii* 3056, *S*. *flexneri* 2a 142, *S*. *flexneri* 3a 144, STm D23580 and SEn Ke016, we setup bactericidal assays against *S*. *sonnei* (using the in-house made strain 71, where *virG* gene was substituted with the chloramphenicol resistance cassette to stabilize O-antigen expression) \[[@pone.0172163.ref018]\], and against *Neisseria meningitidis* serogroups A and W, using the invasive African strains Niga 16/09 and Mali 4/11, respectively. A standard reference pooled serum was used for the SBA assay against *S*. *sonnei*. For *N*. *meningitidis* seroroup A and W, we used mAbs against the capsular polysaccharide types A and W, respectively. [Fig 5](#pone.0172163.g005){ref-type="fig"} shows the complete panel of the bacterial species tested in our study using standard reference sera or mAbs as a source of bactericidal antibodies. The serum titers obtained by L-SBA were similar (almost identical for *S*. Typhimurium, *S*. Enteritidis and *S*. *sonnei)* to the titers obtained by the conventional CFU-based assay ([Fig 5](#pone.0172163.g005){ref-type="fig"} and [Table 4](#pone.0172163.t004){ref-type="table"}). Most importantly, we observed a very low variability among the replicates of L-SBA titers ([Fig 5](#pone.0172163.g005){ref-type="fig"} and [Table 4](#pone.0172163.t004){ref-type="table"}).

![Comparison of titers obtained by the conventional SBA assay and by L-SBA, using a panel of standard reference sera or mAbs against different bacterial species.\
White or grey bars represent the SBA titers calculated from the conventional CFU-counts or from L-SBA, respectively. Standard reference sera were used against *C*. *freundii*, *S*. Typhimurium, *S*. Enteritidis, *S*. *flexneri 2a and 3a* and *S*. *sonnei*. For *N*. *meningitidis* A and W anti-capsular mAbs were used. The results are the mean ± standard deviation values from three independent experiments.](pone.0172163.g005){#pone.0172163.g005}

10.1371/journal.pone.0172163.t004

###### Serum titers and standard deviation (SD) values shown in [Fig 5](#pone.0172163.g005){ref-type="fig"}.

![](pone.0172163.t004){#pone.0172163.t004g}

                    *C*. *freundii*   *S*. Typhimurium   *S*. Enteritidis   *S*. *flexneri 2a*   *S*. *flexneri 3a*   *S*. *sonnei*   *N*. *meningitidis A*   *N*. *meningitidis W*                                                                                                           
  ----------------- ----------------- ------------------ ------------------ -------------------- -------------------- --------------- ----------------------- ----------------------- ---- ------- ------- ---- -------- ------- ---- ------ ----- --- -------- ------- ---- -------- ------- ----
  **CFU titer**     3367              1260               37                 42438                1984                 5               12073                   2385                    20   75739   13186   17   334733   42452   13   2505   54    2   101058   12723   13   106520   29899   28
  **L-SBA titer**   2517              277                11                 45917                4335                 9               11022                   2579                    23   91552   3046    3    404457   59866   15   2331   206   9   76564    9390    12   56651    3981    7

### Assessment of sera with different bactericidal potential against *N*. *meningitidis* by L-SBA {#sec017}

With *N*. *meningitidis* A and W strains, two additional pooled mouse sera, raised to meningococcal GMMA were also assayed. For the SBA with *N*. *meningitidis* A, serum pool n° 4 was raised to a lower dose of GMMA (0.2 μg), consequently, as expected, showed less bactericidal activity than serum pool n° 2, raised to a higher dose (5 μg). The two SBA methods gave similar bactericidal curves for the serum pool 4 and similar curves for the serum pool 2, with a lower variability among the replicates of L-SBA ([Fig 6A and 6B](#pone.0172163.g006){ref-type="fig"} and [Table 5](#pone.0172163.t005){ref-type="table"}). Similarly for *N*. *meningitidis* W, we selected two pooled mouse sera raised to different meningococcal GMMA with different bactericidal activity and obtained similar results in the comparison to that obtained with the anti-*N*. *meningitidis* A sera pools ([Fig 6C and 6D](#pone.0172163.g006){ref-type="fig"}).

![Comparison of L-SBA and conventional assay using pooled mouse sera against *Neisseria meningitidis* serogroups A and W.\
HI pooled mouse sera were tested by L-SBA (A, C) or by conventional assay (B, D) against *N*. *meningitidis* A Niga 16/09 strain (A, B) or *N*. *meningitidis* W Mali 4/11 strain (C, D). Results are the mean ± standard deviation values from three replicates (for some points the error bars are not visible because shorter than the symbols).](pone.0172163.g006){#pone.0172163.g006}

10.1371/journal.pone.0172163.t005

###### Serum titers with 95% Confidence Interval (CI) limits from bactericidal reactions shown in [Fig 6](#pone.0172163.g006){ref-type="fig"} against *N*. *meningitidis* A (MenA) and *N*. *meningitidis* W (MenW).

![](pone.0172163.t005){#pone.0172163.t005g}

  ----------------- ------------------ ------------------------ ------------------------ ---------- ------------------------ ------------------------
  **MenA**          **serum pool 2**   **serum pool 4**                                                                      
                    **Mean**           **95% CI Upper limit**   **95% CI Lower limit**   **Mean**   **95% CI Upper limit**   **95% CI Lower limit**
  **L-SBA titer**   21661              25438                    18415                    3044       4121                     2345
  **CFU titer**     28892              48280                    20477                    3943       4928                     3175
  **MenW**          **serum pool 6**   **serum pool 2**                                                                      
                    **Mean**           **95% CI Upper limit**   **95% CI Lower limit**   **Mean**   **95% CI Upper limit**   **95% CI Lower limit**
  **L-SBA titer**   33481              38057                    29447                    20881      22354                    19544
  **CFU titer**     82178              nd                       69976                    28803      30942                    26605
  ----------------- ------------------ ------------------------ ------------------------ ---------- ------------------------ ------------------------

Discussion {#sec018}
==========

SBA assay is the method of choice to evaluate the complement-mediated functional activity of vaccine-induced antibodies targeting several pathogenic microorganisms \[[@pone.0172163.ref001], [@pone.0172163.ref025], [@pone.0172163.ref026]\], and for organisms such as *N*. *meningitidis* serogroup B, it is considered the gold standard correlate of protection \[[@pone.0172163.ref005]\].

In the present study, we successfully tested L-SBA with multiple Gram-negative bacteria: *Citrobacter freundii*, *Salmonella* Typhimurium and Enteritidis, *Shigella flexneri* serogroups 2a and 3a, *Shigella sonnei*, and *Neisseria meningitidis* serogroups A and W, demonstrating a broad applicability of using an ATP detection method for quantifying surviving bacteria. Most important with all the target bacteria tested, we obtained highly reproducible data and a strong correlation between serum titers, as determined by traditional CFU counting method and by L-SBA.

Because the L-SBA eliminates the labor-intensive steps of plating the reaction mixtures and counting individual CFU, it brings significant advantages over the conventional assay ([Table 6](#pone.0172163.t006){ref-type="table"}) in terms of: 1. reduced *in vitro* assay time; 2. faster data acquisition and analysis, as the luminescence signal in the SBA reaction is directly measured by a microplate reader instead of CFU counting; 3. high reproducibility and operator independency, as bacteria quantitation does not rely upon plating of serial dilutions of the reaction mixtures; 4. higher throughput: in our standard manual L-SBA we routinely test 24 serially diluted individual sera at 8 different concentrations in triplicate (576 data points, not counting controls) in one day. By contrast, in the conventional SBA assay the number of sera to be tested in a manual assay is limited by the number of agar plates to be plated and counted, and in our standard conventional SBA we are able to test 12 sera with 8 dilutions each with a single replicate (96 data points not counting controls) over two days. Furthermore, unlike the conventional SBA that even with automation suffers of major limits in handling large number of plates, the L-SBA assay may further increase its throughput through the use of robotic systems.

10.1371/journal.pone.0172163.t006

###### Comparison between L-SBA and traditional CFU-based assay in terms of procedure advantages.

![](pone.0172163.t006){#pone.0172163.t006g}

                                L-SBA                                                                   traditional SBA with manual counts
  ----------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  **Total time of execution**   6 hours[^1^](#t006fn001){ref-type="table-fn"}                           1.5 working day[^2^](#t006fn002){ref-type="table-fn"}
  **Data acquisition**          2 minutes/SBA plate                                                     2--3 hours/SBA plate[^2^](#t006fn002){ref-type="table-fn"}
  **Reproducibility**           higher operator independency                                            lower operator independency
  **Assay throughput**          1 operator/day: 24 individual sera in triplicate (6 SBA plates total)   1 operator/1.5 day: 12 individual sera in single (1 SBA plate[^2^](#t006fn002){ref-type="table-fn"})

^1^to execute 1 set of 6 SBA plates

^2^to execute 1 SBA plate, plating each reaction well in 1 full agar plate: 1 SBA plate corresponds to have 96 agar plates

Previous attempts to develop non-agar-based readout methods for bactericidal reactions were based on fluorescence or colorimetry, e.g., the metabolic indicator alamarBlue \[[@pone.0172163.ref014], [@pone.0172163.ref027]\], that in the presence of cellular respiration is reduced, exhibiting both a fluorescence change and a colorimetric change. However, those methods require further incubation or kinetic measurement of the bacteria at the end of the bactericidal reactions \[[@pone.0172163.ref027]\] and cannot be performed without automatized robotic equipment. On the contrary, L-SBA is an end-point assay and results are acquired and analyzed on the same day of the assay execution, with no dependence on special equipment but a luminometer microplate reader.

Collectively, our results demonstrate that L-SBA is a sensitive, reproducible and easy to perform method, particularly promising for large-scale studies, which are unfeasible using the traditional agar plate-based assay. Possible applications may include: testing panels of bacterial strains, representatives of different antigens structure and fine antibody specificities; screening high number of human sera as possible complement sources; evaluating correlates of protection in animal models or monitor how SBA specificities change along with antibody maturation and immunoglobulin subclasses; conducting epidemiological studies with large panels of isolates to screen their antigenic diversity and other factors such as sensitivity to SBA. Ultimately, in late stage vaccine development, a rapid and robust SBA method may guide identification of best formulation and optimal dose and schedule, and more importantly may be part of large vaccine efficacy trials.

Supporting information {#sec019}
======================

###### Raw values and calculated span in luminescence and CFU/mL for data shown in [Fig 1A](#pone.0172163.g001){ref-type="fig"}.

(PDF)

###### 

Click here for additional data file.

###### Interference of BRS with luminescence reading.

Without washing steps, increasing concentrations of BRS led to high luminescence values (up to 978 CPS using 50% BRS), compared to 5% BRS (252 CPS) (circle ●). Measuring by luminescence the killing effect of 50% BRS for *C*. *freundii* (inducing 99% killing), we observed that, without washing step, luminescence was overestimated (square ■), while one washing step decreased the value by almost three times (triangle ▲).

(TIF)

###### 

Click here for additional data file.
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